Jeremy M Force, DO

Assistant Professor of Medicine
Member of the Duke Cancer Institute
Email address jeremy.force@duke.edu

Education and Training

  • Hematology/Oncology Fellowship, Medicine, Duke University School of Medicine, 2014 - 2017
  • Internal Medicine Residency, Indiana University School of Medicine, 2011 - 2014
  • D.O., University of New England, 2011

Publications

Shariff, AI, Syed, S, Shelby, RA, Force, J, Clarke, JM, D'Alessio, D, and Corsino, L. "Novel cancer therapies and their association with diabetes." Journal of Molecular Endocrinology 62, no. 2 (February 2019): R187-R199. (Review)

PMID
30532995
Full Text

Force, J, Howie, LJ, Abbott, SE, Bentley, R, Marcom, PK, Kimmick, G, Westbrook, K, Sammons, SL, Parks, M, Topping, DL, Emerson, R, Broadwater, G, Hyslop, T, Blackwell, KL, and Nair, SK. "Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype." Clinical Breast Cancer 18, no. 5 (October 2018): 410-417.

PMID
29615305
Full Text

Ong, CT, Campbell, BM, Thomas, SM, Greenup, RA, Plichta, JK, Rosenberger, LH, Force, J, Hall, A, Hyslop, T, Hwang, ES, and Fayanju, OM. "Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database." Annals of Surgical Oncology 25, no. 8 (August 2018): 2249-2260.

PMID
29855830
Full Text

Thomas, SM, Fayanju, OM, Plichta, JK, Rosenberger, LH, Force, J, Hyslop, T, Hwang, ES, and Greenup, RA. "Treatment Patterns and Outcomes for Breast Cancer with Isolated Supraclavicular Metastases." 71st Annual Cancer Symposium of the Society-of-Surgical-Oncology. Chicago, IL. March 21, 2018 - March 24, 2018.: SPRINGER, February 1, 2018.

Scholars@Duke

Ong, CT, Thomas, SM, Campbell, BM, Greenup, RA, Plichta, JK, Rosenberger, LH, Force, JM, Hyslop, T, Hwang, E-SS, and Fayanju, OM. "A population-based analysis of treatment and outcomes in 2,500 meta plastic breast cancer patients." May 20, 2017.

Full Text

Campbell, BM, Thomas, SM, Ong, CT, Greenup, RA, Plichta, JK, Rosenberger, LH, Force, JM, Hyslop, T, Hwang, E-SS, and Fayanju, OM. "The epidemiology of metaplastic breast cancer: A review of 2,500 cases from the national cancer database." May 20, 2017.

Full Text

Force, J, Abbott, S, Broadwater, G, Kimmick, G, Westbrook, K, Hwang, S, Kauff, N, Stashko, I, Weinhold, K, Nair, S, Hyslop, T, Blackwell, K, Castellar, E, and Marcom, P. "Abstract P2-04-19: Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA mutated breast cancer patients." February 15, 2017.

Full Text

Force, J, and Salama, AK. "First-line treatment of metastatic melanoma: role of nivolumab." ImmunoTargets and therapy 6 (January 2017): 1-10. (Review)

PMID
28243579
Full Text

Spiegel, D, Marcom, PK, Peterson, B, Force, J, Howie, L, Palta, M, Blitzblau, RC, and Horton, JK. "Acute Toxicity in Patients With HER2-Positive Breast Cancer Treated With Adjuvant Radiation Therapy and Concurrent Trastuzumab and Pertuzumab." International journal of radiation oncology, biology, physics 96, no. 2S (October 2016): E9-E10.

PMID
27675495
Full Text

Force, JM, Howie, LJ, Abbottt, S, Bentley, RC, Marcom, PK, Kimmick, GG, Westbrook, KE, Parks, M, Topping, DL, Broadwater, G, Blackwell, KL, and Nair, SK. "Increased FoxP3 and PD-L1 in non-pCR tissue from early stage HER2 positive breast cancer patients treated with trastuzumab-pertuzumab based regimens." May 20, 2016.

Full Text

Pages